Table 3. Study indicators as measured at baseline (B) and the end (E) of the study for all patients and minority patients within each of the 3 practices.

| Study Indicator | Practice A |  |  |  | Practice B |  |  |  | Practice C |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Black <br> Patients |  | White Patients |  | Hispanic Patients |  | White Patients |  | Black Patients |  | White Patients |  |
|  | B | E | B | E | B | E | B | E | B | E | B | E |
| Hypertension |  |  |  |  |  |  |  |  |  |  |  |  |
| BP in 12 months | 90.5\% | 92.5\%* | 89.6\% | 89.8\% | 85.0\% | 87.8\%* | 88.0\% | 87.6\% | 97.3\% | 99.1\%* | 98.1\% | 99.2\% |
| Dx HTN 3 BP >=140/90 | 88.9\% | 97.1\%* | 88.8\% | 94.8\% | - | - | 56.1\% | 68.3\% | - | 91.7\% | 88.9\% | 81.5\% |
| BP in 3 months HTN patients | 63.7\% | 67.9\%* | 61.5\% | 65.6\% | 38.9\% | 33.3\%* | 67.5\% | 48.0\% | 56.0\% | 60.0\%** | 56.3\% | 53.9\% |
| Last BP <140/90 all patients | 54.9\% | 70.4\% | 56.9\% | 76.0\% | 78.3\% | 87.2\% | 73.0\% | 83.2\% | 86.4\% | 96.7\%* | 87.9\% | 90.7\% |
| Last BP <140/90 HTN patients | 38.6\% | 64.0\% | 44.5\% | 72.0\% | 33.3\% | 50.0\% | 32.3\% | 59.5\% | 60.0\% | 63.2\% | 65.7\% | 72.4\% |
| Hyperlipidemia |  |  |  |  |  |  |  |  |  |  |  |  |
| Cholesterol in 60 months | 74.3\% | 86.0\%* | 80.0\% | 87.7\% | - | 75.1\% | - | 66.8\% | - | 38.9\% | - | 40.0\% |
| HDL-C in 60 months | 72.1\% | 85.0\%* | 77.0\% | 85.6\% | - | 74.7\% | - | 67.2\% | - | 38.5\% | - | 40.0\% |
| Coronary Heart Disease |  |  |  |  |  |  |  |  |  |  |  |  |
| LDL-C in 12 months | 85.7\% | 92.9\%* | 83.3\% | 84.2\% | - | - | 41.7\% | 61.9\% | - | - | - | 42.9\% |
| Dx hyperlipidemia LDL-C > 130 | - | - | 96.7\% | 94.7\% | - | - | - | - | - | - | - | - |
| Rx for LDL-C >130 | - | - | 73.3\% | 52.6\% | - | - | - | - | - | - | - | - |
| Beta-blocker MI patients | - | - | - | - | - | - | - | - | - | - | - | - |
| Last LDL-C <100 | 50.0\% | 46.2\% | 34.3\% | 53.6\% | - | - | 40.0\% | 46.2\% | - | - | - | - |
| Last BP <140/90 | 84.6\% | 71.4\% | 49.2\% | 80.9\% | - | - | 52.4\% | 66.7\% | - | - | - | - |
| Heart Failure |  |  |  |  |  |  |  |  |  |  |  |  |
| Rx for ACE or ARB | - | - | 66.0\% | 71.7\% | - | - | - | - | - | - | - | 69.2\% |
| Atrial Fibrillation |  |  |  |  |  |  |  |  |  |  |  |  |
| Rx of oral anti-coagulant | - | - | 47.6\% | 58.3\% | - | - | - | - | - | - | - | - |
| Diabetes Mellitus |  |  |  |  |  |  |  |  |  |  |  |  |
| HgbA1c in 12 months | 82.6\% | 81.3\% | 60.7\% | 90.4\% | - | 92.9\% | - | 67.0\% | - | 40.9\% | - | 44.4\% |
| LDL-C in 24 months | 82.6\% | 90.6\%* | 86.9\% | 94.9\% | 45.5\% | 78.6\%* | 56.9\% | 80.2\% | - | 59.1\% | - | 68.1\% |
| BP in 3 months | 73.9\% | 75.0\% | 70.5\% | 72.1\% | 45.5\% | 21.4\% | 68.6\% | 52.8\% | 64.3\% | 59.1\%* | 48.7\% | 43.1\% |
| Last HgbA1c < 7 | 63.2\% | 46.2\% | 56.8\% | 48.7\% | - | 38.5\% | - | 55.7\% | - | - | - | - |
| Last LDL-C < 100 | 35.3\% | 46.4\% | 40.0\% | 56.3\% | - | - | 25.0\% | 40.0\% | - | - | - | 40.0\% |
| Last BP <130/85 | 43.5\% | 65.6\% | 44.8\% | 78.8\% | 63.6\% | 66.7\% | 54.2\% | 64.4\% | 78.6\% | 68.2\% | 77.8\% | 73.2\% |

Abbreviations
BP: blood pressure; Dx: diagnosis; HTN: hypertension; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; MI: past history of myocardial infarction; Rx: prescription; ACE: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; HgbA1c: hemoglobin A1c

Note: When the number of subjects for the denominator of a given measure was $<10$, or if sufficient lab data were not recorded to calculate the measure of interest, the data are not considered reliable and thus indicated by a dash in the above table.

* Improvement (end-of-study - baseline) in minority group was greater than that observed for all patients.

